TP63 and cancer: Moreover, we find that SREBF1 cooperates with TP63/KLF5 to regulate hundreds of cis-regulatory elements across the SCC-specific epigenome, which converges on activating cancer-promoting pathways, uncovering SREBF1 as a potential therapeutic target and prognostic marker in SCC.